Investing.com - Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) reported first quarter EPS of $-0.0200, in line with the analyst estimate of $-0.0200. Revenue for the quarter came in at $2.06M versus the consensus estimate of $1.6M.
Adamis Pharmaceuticals Corporation's stock price closed at $0.1200. It is down -20.0000% in the last 3 months and down -79.9100% in the last 12 months.
Adamis Pharmaceuticals Corporation saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Adamis Pharmaceuticals Corporation's stock price’s past reactions to earnings here.
According to InvestingPro, Adamis Pharmaceuticals Corporation's Financial Health score is "weak performance".
Check out Adamis Pharmaceuticals Corporation's recent earnings performance, and Adamis Pharmaceuticals Corporation's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar